Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2426 - 2450 of 3539 in total

SIS-101-ADO

SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational

NKX101

NKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.
Investigational

AXV101

Investigational

Xevinapant

Investigational

Sri-9439

Experimental

CRA_9076

Experimental

CRA_9678

Experimental

DP-b99

DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft.
Investigational

AZD-9056

AZD9056 has been used in trials studying the basic science and treatment of Rheumatoid Arthritis.
Investigational

AZD-9496

AZD-9496 is under investigation in clinical trial NCT02248090 (AZD9496 First Time in Patients Ascending Dose Study).
Investigational

CP-96345

Experimental

PD-98059

PD-98059 is an inhibitor of MAP-kinase kinase activation.
Investigational

ZK-93423

ZK-93423 is a beta-carboline with muscle relaxant activity with agonistic properties at the benzodiazepine receptor.
Investigational

BLU-9931

Investigational

CC-90001

Investigational

N-(6,7,9,10,17,18,20,21-octahydrodibenzo[b,k][1,4,7,10,13,16]hexaoxacyclooctadecin-2-yl)acetamide

Experimental

CRA_10991

Experimental

CRA_10762

Experimental

RB106

Experimental

CRA_10972

Experimental

CRA_10656

Experimental

TG-100801

TG100801 is a topically applied kinase inhibitor in macular degeneration patients. It is administered noninvasively as an eye drop and is designed to suppress VEGF mediated leakage and additional kinase targets associated with inflammation, edema, and angiogenesis which are the pathological hallmarks of AMD and other back of the eye...
Investigational

KB109

KB109 is a prebiotic to feed healthy bacteria for them to to outcompete multi-drug resistance organisms.
Investigational

P-BCMA-101

P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.
Investigational

AP103

AP103 is a non-viral gene therapy that uses a delivery vector, HPAE (Highly Branched Poly β-Amino Ester), to deliver the correct collagen VII gene into skin cells.
Investigational
Displaying drugs 2426 - 2450 of 3539 in total